“The first steps are to gain comfort that the intervention with afamelanotide poses no harm to patients, while obtaining objective measures of impact of treatment on the course of the patients’ disease. With CUV801 we have achieved both these outcomes and can now pursue further studies and regulatory interactions with a degree of confidence that the drug performs as expected.”
Yes, I agree, it wasn't presented, but I believe that it was inferred by the MRI-FLAIR indications they saw, It inferred that they were better than what is normally seen. Note 2 seems to suggest that.
Highlights by me.
GLA
- Forums
- ASX - By Stock
- Ann: Positive Final Results in Stroke Study CUV801
“The first steps are to gain comfort that the intervention with...
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CUV (ASX) to my watchlist
|
|||||
Last
$14.84 |
Change
0.260(1.78%) |
Mkt cap ! $743.1M |
Open | High | Low | Value | Volume |
$14.61 | $14.99 | $14.40 | $1.349M | 91.96K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 644 | $14.79 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.85 | 3489 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 644 | 14.790 |
1 | 234 | 14.660 |
1 | 234 | 14.620 |
1 | 100 | 14.600 |
1 | 234 | 14.580 |
Price($) | Vol. | No. |
---|---|---|
14.880 | 2000 | 1 |
14.940 | 30 | 1 |
14.950 | 2564 | 1 |
14.960 | 1359 | 2 |
15.000 | 3020 | 2 |
Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
Featured News
CUV (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online